Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
13 11 2019
Historique:
received: 02 10 2018
accepted: 15 01 2019
pubmed: 5 2 2019
medline: 15 9 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

This study analyzed the relationship between vancomycin area under the concentration-time curve (AUC) and acute kidney injury (AKI) reported across recent studies. A systematic review of PubMed, Medline, Scopus, and compiled references was conducted. We included randomized cohort and case-control studies that reported vancomycin AUCs and risk of AKI (from 1990 to 2018). The primary outcome was AKI, defined as an increase in serum creatinine of ≥0.5 mg/L or a 50% increase from baseline on ≥2 consecutive measurements. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Primary analyses compared the impact of AUC cutpoint (greater than ~650 mg × hour/L) and AKI. Additional analysis compared AUC vs trough-guided monitoring on AKI incidence. Eight observational studies met inclusion/exclusion criteria with data for 2491 patients. Five studies reported first-24-hour AUCs (AUC0-24) and AKI, 2 studies reported 24- to 48-hour AUCs (AUC24-48) and AKI, and 2 studies reported AKI associated with AUC- vs trough-guided monitoring. AUC less than approximately 650 mg × hour/L was associated with decreased AKI for AUC0-24 (OR, 0.36 [95% CI, .23-.56]) as well as AUC24-48 (OR, 0.45 [95% CI, .27-.75]). AKI associated with the AUC monitoring strategy was significantly lower than trough-guided monitoring (OR, 0.68 [95% CI, .46-.99]). AUCs measured in the first or second 24 hours and lower than approximately 650 mg × hour/L may result in a decreased risk of AKI. Vancomycin AUC monitoring strategy may result in less vancomycin-associated AKI. Additional investigations are warranted.

Sections du résumé

BACKGROUND
This study analyzed the relationship between vancomycin area under the concentration-time curve (AUC) and acute kidney injury (AKI) reported across recent studies.
METHODS
A systematic review of PubMed, Medline, Scopus, and compiled references was conducted. We included randomized cohort and case-control studies that reported vancomycin AUCs and risk of AKI (from 1990 to 2018). The primary outcome was AKI, defined as an increase in serum creatinine of ≥0.5 mg/L or a 50% increase from baseline on ≥2 consecutive measurements. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Primary analyses compared the impact of AUC cutpoint (greater than ~650 mg × hour/L) and AKI. Additional analysis compared AUC vs trough-guided monitoring on AKI incidence.
RESULTS
Eight observational studies met inclusion/exclusion criteria with data for 2491 patients. Five studies reported first-24-hour AUCs (AUC0-24) and AKI, 2 studies reported 24- to 48-hour AUCs (AUC24-48) and AKI, and 2 studies reported AKI associated with AUC- vs trough-guided monitoring. AUC less than approximately 650 mg × hour/L was associated with decreased AKI for AUC0-24 (OR, 0.36 [95% CI, .23-.56]) as well as AUC24-48 (OR, 0.45 [95% CI, .27-.75]). AKI associated with the AUC monitoring strategy was significantly lower than trough-guided monitoring (OR, 0.68 [95% CI, .46-.99]).
CONCLUSIONS
AUCs measured in the first or second 24 hours and lower than approximately 650 mg × hour/L may result in a decreased risk of AKI. Vancomycin AUC monitoring strategy may result in less vancomycin-associated AKI. Additional investigations are warranted.

Identifiants

pubmed: 30715208
pii: 5305676
doi: 10.1093/cid/ciz051
pmc: PMC6853683
doi:

Substances chimiques

Anti-Bacterial Agents 0
Vancomycin 6Q205EH1VU

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1881-1887

Subventions

Organisme : NIAID NIH HHS
ID : R15 AI105742
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

PLoS Med. 2012;9(10):e1001333
pubmed: 23222917
Clin Infect Dis. 2009 Aug 1;49(3):325-7
pubmed: 19569969
Ann Pharmacother. 2017 Mar;51(3):185-193
pubmed: 27838680
Chemotherapy. 2012;58(4):308-12
pubmed: 23147106
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28242672
Clin Infect Dis. 2012 Mar;54(6):755-71
pubmed: 22302374
Infect Control Hosp Epidemiol. 2016 Jan;37(1):70-9
pubmed: 26456803
Int J Antimicrob Agents. 2018 Feb;51(2):239-243
pubmed: 28803934
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29084753
Clin Infect Dis. 2012 Mar 1;54(5):621-9
pubmed: 22247123
Int J Antimicrob Agents. 2018 Dec;52(6):805-810
pubmed: 30176357
Clin Ther. 2012 Jan;34(1):149-57
pubmed: 22284995
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923869
Int J Antimicrob Agents. 2015 Sep;46(3):249-53
pubmed: 26141230
Clin Pharmacol Ther. 2017 Sep;102(3):459-469
pubmed: 28474732
Crit Care Med. 2014 Dec;42(12):2527-36
pubmed: 25083977
J Antimicrob Chemother. 2009 May;63(5):849-61
pubmed: 19282331
Clin Infect Dis. 2011 Feb 1;52(3):285-92
pubmed: 21217178
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51
pubmed: 27431226
Pharmacotherapy. 2015 Oct;35(10):889-98
pubmed: 26497475
Clin Infect Dis. 2009 Aug 15;49(4):507-14
pubmed: 19586413
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263057
Clin Infect Dis. 2011 Apr 15;52(8):969-74
pubmed: 21460308
BMC Infect Dis. 2014 Apr 04;14:183
pubmed: 24708675
Eur J Clin Pharmacol. 2012 Sep;68(9):1243-55
pubmed: 22411630
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29203493
Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6
pubmed: 18227177
Ann Pharmacother. 2012 Nov;46(11):1477-83
pubmed: 23073306
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12
pubmed: 16323120
Antimicrob Agents Chemother. 2014;58(1):309-16
pubmed: 24165176
J Antimicrob Chemother. 2012 Jan;67(1):17-24
pubmed: 22028203
BMC Pharmacol Toxicol. 2013 Feb 13;14:12
pubmed: 23402420
Clin Infect Dis. 2020 Apr 10;70(8):1536-1545
pubmed: 31157370
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28807910

Auteurs

Doaa M Aljefri (DM)

Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois.
Department of Pharmacy, King Abdulaziz Medical City, Jeddah, Saudi Arabia.

Sean N Avedissian (SN)

Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois.
Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.
Center of Pharmacometric Excellence, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.

Nathaniel J Rhodes (NJ)

Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois.
Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.
Center of Pharmacometric Excellence, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.

Michael J Postelnick (MJ)

Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois.

Kevin Nguyen (K)

Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.

Marc H Scheetz (MH)

Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois.
Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.
Center of Pharmacometric Excellence, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.
Department of Pharmacology, College of Graduate Studies, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH